Los Angeles Capital Management LLC Has $15.29 Million Stock Holdings in BioMarin Pharmaceutical Inc. $BMRN

Los Angeles Capital Management LLC lifted its position in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) by 97.2% in the second quarter, according to its most recent disclosure with the SEC. The institutional investor owned 278,189 shares of the biotechnology company’s stock after buying an additional 137,135 shares during the quarter. Los Angeles Capital Management LLC’s holdings in BioMarin Pharmaceutical were worth $15,292,000 as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of BMRN. V Square Quantitative Management LLC acquired a new stake in BioMarin Pharmaceutical in the 2nd quarter worth about $25,000. Rise Advisors LLC acquired a new stake in shares of BioMarin Pharmaceutical in the first quarter valued at approximately $30,000. Brooklyn Investment Group grew its position in BioMarin Pharmaceutical by 2,250.0% during the first quarter. Brooklyn Investment Group now owns 564 shares of the biotechnology company’s stock worth $40,000 after buying an additional 540 shares in the last quarter. Hantz Financial Services Inc. increased its stake in BioMarin Pharmaceutical by 480.2% during the 2nd quarter. Hantz Financial Services Inc. now owns 1,056 shares of the biotechnology company’s stock worth $58,000 after acquiring an additional 874 shares during the period. Finally, Banque Transatlantique SA acquired a new stake in shares of BioMarin Pharmaceutical during the 1st quarter worth $71,000. Institutional investors own 98.71% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms recently weighed in on BMRN. Sanford C. Bernstein cut their price objective on shares of BioMarin Pharmaceutical from $95.00 to $88.00 and set an “outperform” rating for the company in a research report on Monday, November 3rd. Wells Fargo & Company reduced their price target on shares of BioMarin Pharmaceutical from $90.00 to $70.00 and set an “overweight” rating on the stock in a research report on Tuesday, October 28th. UBS Group boosted their price objective on shares of BioMarin Pharmaceutical from $113.00 to $114.00 and gave the company a “buy” rating in a research report on Tuesday, August 5th. Barclays dropped their price objective on BioMarin Pharmaceutical from $86.00 to $80.00 and set an “overweight” rating for the company in a research report on Tuesday, October 28th. Finally, Zacks Research downgraded shares of BioMarin Pharmaceutical from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, August 13th. Sixteen research analysts have rated the stock with a Buy rating, six have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, BioMarin Pharmaceutical currently has a consensus rating of “Moderate Buy” and a consensus price target of $89.91.

BioMarin Pharmaceutical Stock Performance

NASDAQ BMRN opened at $51.46 on Friday. The company has a market capitalization of $9.89 billion, a price-to-earnings ratio of 19.35, a PEG ratio of 0.68 and a beta of 0.33. The company has a quick ratio of 3.60, a current ratio of 4.83 and a debt-to-equity ratio of 0.10. BioMarin Pharmaceutical Inc. has a twelve month low of $50.76 and a twelve month high of $73.51. The stock has a fifty day simple moving average of $54.19 and a 200 day simple moving average of $56.82.

BioMarin Pharmaceutical Company Profile

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.